Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis

• Главные авторы: Delphine Staumont‐Sallé (Автор), Sébastien Barbarot (Автор), Jean David Bouaziz (Автор), Chan Chan (Автор), Claire Clibborn (Автор), Aurélie Du‐Thanh (Автор), Claire Feeney (Автор), Alexandre Lejeune (Автор), Laurent Misery (Автор), Audrey Nosbaum (Автор), Julien Seneschal (Автор), Angèle Soria (Автор), Fan Zhang (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2023-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Background Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase‐1 inhibitor and dupilumab, an anti-interleukin‐4 receptor‐α antibody, are approved for moderate‐to‐severe AD. Dupilumab has been associated with transient eosinophilia. Objectives To...